EP0213811A3 - Bateriocin-targeted compounds for cancer therapy - Google Patents

Bateriocin-targeted compounds for cancer therapy Download PDF

Info

Publication number
EP0213811A3
EP0213811A3 EP86306115A EP86306115A EP0213811A3 EP 0213811 A3 EP0213811 A3 EP 0213811A3 EP 86306115 A EP86306115 A EP 86306115A EP 86306115 A EP86306115 A EP 86306115A EP 0213811 A3 EP0213811 A3 EP 0213811A3
Authority
EP
European Patent Office
Prior art keywords
bateriocin
cancer therapy
targeted compounds
targeted
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP86306115A
Other languages
German (de)
French (fr)
Other versions
EP0213811A2 (en
Inventor
Donald H. Picker
Anthony Serino, Jr.
Geoffrey W. Henson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson Matthey Inc
Original Assignee
Johnson Matthey Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson Matthey Inc filed Critical Johnson Matthey Inc
Publication of EP0213811A2 publication Critical patent/EP0213811A2/en
Publication of EP0213811A3 publication Critical patent/EP0213811A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compositions comprising a bacteriocin or active frag­ ment thereof linked directly or indirectly to an antitumor com­ pound, radioisotope, boron-10 containing compound, radio­ sensitizer, or other therapeutic or analytical agent.
EP86306115A 1985-08-16 1986-08-07 Bateriocin-targeted compounds for cancer therapy Withdrawn EP0213811A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76636085A 1985-08-16 1985-08-16
US766360 1985-08-16

Publications (2)

Publication Number Publication Date
EP0213811A2 EP0213811A2 (en) 1987-03-11
EP0213811A3 true EP0213811A3 (en) 1987-09-09

Family

ID=25076199

Family Applications (1)

Application Number Title Priority Date Filing Date
EP86306115A Withdrawn EP0213811A3 (en) 1985-08-16 1986-08-07 Bateriocin-targeted compounds for cancer therapy

Country Status (2)

Country Link
EP (1) EP0213811A3 (en)
JP (1) JPS6296429A (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL88480A0 (en) * 1987-11-27 1989-06-30 Univ Toronto Proteinaceous compositions
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
CN1080086C (en) * 1996-11-29 2002-03-06 株式会社久保田 Sieve box structure for threshing apparatus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049486A1 (en) * 1980-10-04 1982-04-14 Byk Gulden Lomberg Chemische Fabrik GmbH Metal complexes for use in the treatment of cancer
WO1983002946A1 (en) * 1982-02-26 1983-09-01 Relyveld, Edgar, Hans Antitumoral agents, such as daunorubicin, having an improved activity, obtention thereof and method for enhancing the activity of antitumoral agents
US4452774A (en) * 1982-04-30 1984-06-05 President And Fellows Of Harvard College Isonitrile radionuclide complexes for labelling and imaging agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049486A1 (en) * 1980-10-04 1982-04-14 Byk Gulden Lomberg Chemische Fabrik GmbH Metal complexes for use in the treatment of cancer
WO1983002946A1 (en) * 1982-02-26 1983-09-01 Relyveld, Edgar, Hans Antitumoral agents, such as daunorubicin, having an improved activity, obtention thereof and method for enhancing the activity of antitumoral agents
US4452774A (en) * 1982-04-30 1984-06-05 President And Fellows Of Harvard College Isonitrile radionuclide complexes for labelling and imaging agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH. vol. 36, October 1976, H. FARKAS-HIMSLEY AND R. CHEUNG: "Bacterial Proteinacious Products (Bacteriocins) as Cytotoxic Agents of Neoplasia", pages 3561-3567 *

Also Published As

Publication number Publication date
EP0213811A2 (en) 1987-03-11
JPS6296429A (en) 1987-05-02

Similar Documents

Publication Publication Date Title
AU590792B2 (en) Chewable capsules
HK24995A (en) Metoprolol succinate and pharmaceutical composition containing it
AU523978B2 (en) Inhalator for powdered medicaments
IL89748A (en) Pharmaceutical compositions for systemic transdermal administration, containing deprenyl
ES8706717A1 (en) Steroids and therapeutic compositions containing same.
ZA8114B (en) Platnum (iv)-diamine-complexes,a process for the preparation thereof ,a process for the preparation of a medicine using such a platinum (iv) -diamine-complex for the treamentof cancer as well as the shaped medicine thus obtained
DE3571982D1 (en) Benzisoselenazolethiones,process for their preparation and pharmaceutical products containing these compounds
JPS52122323A (en) Platinum coordination compound* preparation thereof* medicine* for cancer* containing same as active constituent
GR78151B (en)
DE3569535D1 (en) Tumor cell growth-inhibiting pharmaceutical compositions containing phosphino-hydrocarbon-gold, silver or copper complexes
JO1406B1 (en) Chemical compounds
AU2027583A (en) Platinum-diamine complexes, a process for the preparation thereof, a process for the preparation of a medical composition using a such platinum-diamine complex for the treatment of cancer, as well as the thus shaped composition
JPS5732300A (en) Organic compound, manufacture and medicinal composition containing same
JPS5776000A (en) Organic compound, manufacture and medicinal compound containing same
EP0213811A3 (en) Bateriocin-targeted compounds for cancer therapy
ES8407009A1 (en) (-)-15-Deoxyspergualin, a process for the preparation of the same, and a pharmaceutical composition containing the same.
IL67849A (en) Panthenol derivatives,their manufacture and pharmaceutical compositions containing them
ES466257A1 (en) Compounds having hypolipidaemic activity
ZA854206B (en) Tumor cell growth-inhibiting pharmaceutical compositions containing phosphino-hydrocarbon-gold,silver or copper complexes
JPS5215829A (en) Medicine containing organosilicon compound as active agent
JPS5759806A (en) Nitroglycerine pad for percutaneous administration
ES8800198A1 (en) N-substituted aziridine-2-carboxylic acid derivatives, process for their preparation as well as medicaments containing these substances.
IL62987A0 (en) Tin compounds,a process for the preparation thereof,a process for the preparation of a medicine using such a tin compound for the treatment of cancer,as well as the shaped medicine thus formed and obtained
ZA813621B (en) Tin compounds,a process for the preparation thereof,a process for the preparation of a medicine using such a tin compound for the treatment of cancer,as well as the shaped medicine thus formed and obtained
SU1226821A1 (en) Mixed silicon-germanium-organic derivatives of catecholamines showing property to increase blood pressure

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19871005

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19890301

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PICKER, DONALD H.

Inventor name: HENSON, GEOFFREY W.

Inventor name: SERINO, ANTHONY, JR.